NCT04826679View on ClinicalTrials.gov

Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC

PHASE2RecruitingINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

April 1, 2023

Study Completion Date

April 1, 2026

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

Camrelizumab, nab-paclitaxel, cisplatin

"Patients receive Camrelizumab IV on day 1, nab-paclitaxel IV on day 1 and cisplatin IV on day 1.~Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity."

Trial Locations (1)

Unknown

RECRUITING

Sun Yat-sen University, Guangzhou

All Listed Sponsors
collaborator

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

lead

Sun Yat-sen University

OTHER